诱导多能干细胞(iPSC):日本京都大学团队计划将iPSC衍生的软骨移植到膝关节中

2020-01-27 Allan MedSci原创

据报道,日本厚生省的一个专家小组批准了由京都大学研究人员提出的一项临床研究计划,该计划旨在将由诱导多能干细胞(iPSC)制成的软骨移植到受损的膝关节中。

据报道,日本厚生省的一个专家小组批准了由京都大学研究人员提出的一项临床研究计划,该计划旨在将由诱导多能干细胞iPSC)制成的软骨移植到受损的膝关节中。日本方面希望该技术在2029年投入实际使用。研究人员计划使用iPSC创建直径为23毫米的软骨,并计划在今年进行首次移植。四人将使用iPSC衍生的软骨进行膝关节受损的移植手术,并将接受一年的监测。

诱导性多能干细胞iPSC),是一种由哺乳动物成体细胞经转入转录因子等手段脱分化形成的多能干细胞,最早由日本学者山中伸弥的研究团队于2006年发现。


原始出处:

https://www.firstwordpharma.com/node/1696109

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-10-30 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-01-30 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-01-29 chengjn
  6. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-01-29 gjsgj
  7. [GetPortalCommentsPageByObjectIdResponse(id=1667154, encodeId=d508166e15426, content=<a href='/topic/show?id=3dae101809cd' target=_blank style='color:#2F92EE;'>#骨移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101809, encryptionId=3dae101809cd, topicName=骨移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbed26112986, createdName=howi, createdTime=Fri Oct 30 05:06:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952943, encodeId=170d1952943a3, content=<a href='/topic/show?id=2940918e65c' target=_blank style='color:#2F92EE;'>#诱导多能干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91876, encryptionId=2940918e65c, topicName=诱导多能干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Jul 24 20:06:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025387, encodeId=7fd9102538eee, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jan 30 20:06:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294521, encodeId=a55d1294521f6, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377784, encodeId=526713e7784b4, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404296, encodeId=fa1d1404296af, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538826, encodeId=86c8153882612, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jan 29 11:06:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-01-29 一叶知秋

相关资讯

盘点:浅析诱导性多能干细胞安全性

诱导性多能干细胞(induced pluripotent stem cells, iPS细胞, 也缩写为iPSC)最初是日本科学家山中伸弥(Shinya Yamanaka)于2006年利用病毒载体将四个转录因子---Oct4, Sox2, Klf4 和c-Myc--导入到小鼠小鼠胚胎或皮肤纤维母细胞中,使其重编程而得到的类似胚胎干细胞的一种干细胞类型,产生的iPS干细胞在形态、基因和蛋白表达、

Nature:利用患者特异性的干细胞培育出类似于成年人的心肌组织

培养出与在行为上类似于天然心肌的人体心脏组织会引发生物医学研究变革,这会使得人们能够在完全控制的条件下研究人体生理学和构建心脏病模型。尽管如今的科学家们能够通过利用从我们任何一个人身体获得的小量血液样本衍生的干细胞来培养许多组织(包括心肌),但是当前的生物工程组织未能显示成年人心脏功能的一些最为重要的特征。人们在此之前还不能够在体外培养出因足够成熟而可用于医学研究的心肌。

Redox Biol:NOX2调节神经发生早期,有作为中枢神经系统疾病药物靶标的潜力

CGD患者缺乏产生ROS的NADPH氧化酶NOX2,因此除表现免疫缺陷外,还表现出认知降低。

Blood:血小板特异性抗体检测的新方法

在人体内,血小板膜糖蛋白多态性具有免疫原性,是引起新生儿同种免疫性血小板减少症等疾病的重要临床免疫反应的原因。来源于携带罕见多态性个体的血小板通常难以获得,使得诊断性检测和输注匹配的血小板具有挑战性。I类HLA抗体经常出现在母体血清中,对血小板反应性同种抗体的检测带来额外的干扰。检测人血小板抗原(HPA) 3和9的同种异体抗体尤其具有挑战性,部分原因是由于位于多态氨基酸附近的细胞类型特异性聚糖的存

2017年2月份生物谷推荐的干细胞研究(上)

2017年2月28日/生物谷BIOON/---即将过去的2月份,有哪些重大的干细胞研究或发现呢?小编梳理了一下这个月生物谷报道的干细胞方面的新闻,供大家阅读。 1.Science子刊:干细胞衍生细胞或有望治疗先天性再生障碍性贫血 doi:10.1126/scitranslmed.aah5645 近日,一项刊登在国际杂志Science Transla

Circ Res:多成像技术测定人iPSC来源的心肌细胞收缩时的机械输出

每次搏动期间心肌细胞通过收缩机制产生维持心脏功能所必需的机械输出,如通过调控肌原纤维缩短肌肉机制。人来源的诱导多能干细胞可以分化为心肌细胞,当将其微图形化时可以更直观的模拟心脏收缩时的机械输出。量化这些细胞的机械输出可以用来测定心脏活动。来自斯坦福大学的学者试图构建一个计算平台来整合分析方法,从显微镜视频中量化单个微图形心肌细胞的机械输出。研究者将包含荧光微珠的可变形聚丙烯酰胺底物上的人类诱导多能